NCT04122066

the Pulmonary Safety of Antihepatitis C Treatment

The Pulmonary Safety of the New Oral Antihepatitis C Treatment

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 50 (estimated)
• Sponsor: Assiut University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

pulmonary side effects of the new regimen of antihepatitis C

Detailed description

Hepatitis C is a liver disease caused by the hepatitis C virus.The hepatitis C virus is a blood borne virus The most common modes of infection are through exposure to small quantities of blood, through injection drug use, unsafe injection practices, unsafe health care, and the transfusion of unscreened blood and blood products. An estimated 71 million people have chronic hepatitis C infection. A significant number of those who are chronically infected will develop cirrhosis and or liver cancer. the treatment of hepatitis C virus (HCV) infection has been difficult, particularly in patients with HCV genotype 1. Reasons for the difficulty include the inherent toxicity and limited efficacy of interferon-based therapy, which has been the cornerstone of anti-HCV efforts during the past 2 decades. Newly available direct-acting antiviral agents (DAAs) have the potential to dramatically improve HCV eradication rates. Despite these new drugs has been characterized by a very low adverse events rate in the published clinical trials Few data are available on pulmonary adverse events based real life studies

Conditions

• Hepatitis C

Interventions

Type	Name	Description
DRUG	sofosbuvir \daclatsvir	study the effect of the new oral antihepatitis C drugs on the respiratory system

Timeline

• Start date: 2020-06-01
• Primary completion: 2022-12-01
• Completion: 2023-12-01
• First posted: 2019-10-10
• Last updated: 2020-03-30

Regulatory

• FDA-regulated drug study